One of the many consequences of the COVID-19 crisis has been difficulty in continuing to enroll and run clinical trials, which typically involve large numbers of people interacting in multiple geographies. In this Executive Update, we highlight a new, risk-based predictive analytical approach, powered by machine learning.
Not a member? Gain Access to the Cutter Experts today — register now to read select open-access articles.
Member/Guest loginForgot your password?